Literature DB >> 16216160

Neurobehavioral effects of interferon therapy.

Alan D Valentine1, Christina A Meyers.   

Abstract

Interferon (IFN) therapy is associated with neuropsychiatric side effects including cognitive dysfunction and mood syndromes of varying severity. These problems are the most common causes of treatment discontinuation. Dose and duration of treatment influence risk of IFN-induced side effects. Rates of IFN-induced depression vary, but approach 50% in recent studies. Presence and severity of depressive symptoms at or before treatment predicts development of mood disorders during IFN therapy. Several possible endocrine and neurotransmitter perturbations may be responsible for IFN neurotoxicity, with recent research suggesting different symptoms clusters are related to different underlying mechanisms. The interpretation of these clusters has been influenced by subjective versus objective evaluation of cognitive function. Effective management of IFN-induced neuropsychiatric side effects should involve pretreatment screening and interval assessment during therapy. Antipsychotic and psychostimulant drugs may be used against cognitive dysfunction. Antidepressants have been shown to be effective against IFN-induced depression and can be very valuable in support of adequate or completed therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16216160     DOI: 10.1007/s11920-005-0042-3

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  43 in total

1.  Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state.

Authors:  L Capuron; A Ravaud
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

2.  Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin.

Authors:  Michael R Kraus; Arne Schäfer; Saskia Wissmann; Peter Reimer; Michael Scheurlen
Journal:  Clin Pharmacol Ther       Date:  2005-01       Impact factor: 6.875

3.  Case of mania induced by withdrawal of interferon-alpha in a patient affected by bipolar disorder.

Authors:  Alessandro Rossi; Daniela Renzetti; Luigi D'Albenzio; Daniela Gianfelice; Artemis Kalyvoka; Osvaldo Rinaldi
Journal:  Psychiatry Clin Neurosci       Date:  2002-12       Impact factor: 5.188

4.  Manic episodes in two patients treated with interferon alpha.

Authors:  D Strite; A D Valentine; C A Meyers
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1997       Impact factor: 2.198

5.  Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.

Authors:  Charles L Raison; Andrey S Borisov; Sherry D Broadwell; Lucile Capuron; Bobbi J Woolwine; Ira M Jacobson; Charles B Nemeroff; Andrew H Miller
Journal:  J Clin Psychiatry       Date:  2005-01       Impact factor: 4.384

6.  Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

Authors:  Lucile Capuron; Jane F Gumnick; Dominique L Musselman; David H Lawson; Andrea Reemsnyder; Charles B Nemeroff; Andrew H Miller
Journal:  Neuropsychopharmacology       Date:  2002-05       Impact factor: 7.853

7.  Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.

Authors:  Lucile Capuron; Charles L Raison; Dominique L Musselman; David H Lawson; Charles B Nemeroff; Andrew H Miller
Journal:  Am J Psychiatry       Date:  2003-07       Impact factor: 18.112

8.  Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon.

Authors:  Peter C Trask; Amber G Paterson; Peg Esper; Jason Pau; Bruce Redman
Journal:  Psychooncology       Date:  2004-08       Impact factor: 3.894

9.  Psychiatric complications of long-term interferon alfa therapy.

Authors:  P F Renault; J H Hoofnagle; Y Park; K D Mullen; M Peters; D B Jones; V Rustgi; E A Jones
Journal:  Arch Intern Med       Date:  1987-09

10.  A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.

Authors:  P Hauser; J Khosla; H Aurora; J Laurin; M A Kling; J Hill; M Gulati; A J Thornton; R L Schultz; A D Valentine; C A Meyers; C D Howell
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

View more
  18 in total

1.  Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration.

Authors:  Lucile Capuron; Giuseppe Pagnoni; Daniel F Drake; Bobbi J Woolwine; James R Spivey; Ronald J Crowe; John R Votaw; Mark M Goodman; Andrew H Miller
Journal:  Arch Gen Psychiatry       Date:  2012-10

2.  Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial.

Authors:  Benjamin J Morasco; Jennifer M Loftis; David W Indest; Samantha Ruimy; John W Davison; Bradford Felker; Peter Hauser
Journal:  Psychosomatics       Date:  2010 Sep-Oct       Impact factor: 2.386

Review 3.  Immune activation and neuroinflammation in alcohol use and HIV infection: evidence for shared mechanisms.

Authors:  Mollie A Monnig
Journal:  Am J Drug Alcohol Abuse       Date:  2016-08-17       Impact factor: 3.829

Review 4.  Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

Authors:  Mark S Sulkowski; Curtis Cooper; Bela Hunyady; Jidong Jia; Pavel Ogurtsov; Markus Peck-Radosavljevic; Mitchell L Shiffman; Cihan Yurdaydin; Olav Dalgard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-08       Impact factor: 46.802

5.  Persistent neurocognitive decline in a clinic sample of hepatitis C virus-infected persons receiving interferon and ribavirin treatment.

Authors:  Jordan E Cattie; Scott L Letendre; Steven Paul Woods; Fatma Barakat; William Perry; Mariana Cherner; Anya Umlauf; Donald Franklin; Robert K Heaton; Tarek Hassanein; Igor Grant
Journal:  J Neurovirol       Date:  2014-10-18       Impact factor: 2.643

Review 6.  Toxoplasma gondii infection and behaviour - location, location, location?

Authors:  Glenn A McConkey; Heather L Martin; Greg C Bristow; Joanne P Webster
Journal:  J Exp Biol       Date:  2013-01-01       Impact factor: 3.312

Review 7.  Neuropsychological sequelae of non-central nervous system cancer and cancer therapy.

Authors:  Jeffrey S Wefel; Mariana E Witgert; Christina A Meyers
Journal:  Neuropsychol Rev       Date:  2008-04-16       Impact factor: 7.444

Review 8.  Hepatitis C: Treatment of difficult to treat patients.

Authors:  Eric G Hilgenfeldt; Alex Schlachterman; Roberto J Firpi
Journal:  World J Hepatol       Date:  2015-07-28

Review 9.  Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review.

Authors:  Arne Schäfer; Hans-Ulrich Wittchen; Jochen Seufert; Michael R Kraus
Journal:  Int J Methods Psychiatr Res       Date:  2007       Impact factor: 4.035

10.  Hepatitis C, stigma and cure.

Authors:  Rui Tato Marinho; David Pires Barreira
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.